Abstract：Objective To study the clinical efficacy of norcantharidin for esophageal cancer patients undergoing radiotherapy and chemotherapy.Methods The clinical data on 68 patients with esophageal cancer treated between May 2015 and February 2017 at Xiangyang Central Hospital was analyzed. The patients were divided into control group and observation group by random number method. Both groups received the same radiotherapy and chemotherapy program, but patients in the observation group were additionally given norcantharidin. The clinical efficacy and safety were reviewed.Results The disease control rate in the observation group(85.29%) was higher than that in control group(73.53%), P<0.05. The incidence of radiation-induced esophagitis in the observation group(47.06%) was lower than that in the control group(79.41%), P<0.05. The dose-limiting toxicity included bone marrow suppression, gastrointestinal symptoms and the damaged liver and kidney function. The incidence of bone marrow suppression and gastrointestinal symptoms was lower than that in the control group, P<0.05.Conclusions Norcantharidin used for treatment of esophageal cancer along with radiotherapy and chemotherapy can enhance clinical efficacy and reduce toxicity.
吴炎卿, 李长江. 去甲斑蝥素对食管癌患者放化疗效果的影响[J]. 武警医学, 2018, 29(2): 182-184.
WU Yanqing, LI Changjiang. Effect of norcantharidin on radiotherapy and chemotherapy among patients of esophageal cancer. Med. J. Chin. Peop. Armed Poli. Forc., 2018, 29(2): 182-184.
Ma J, Teng H, Wang J, et al. A highly stable norcantharidin loaded lipid microspheres: Preparation, biodistribution and targeting evaluation[J]. Int J Pharm, 2014,473(1/2):475-484.
[8]
Tu G G, Zhan J F, Lv Q L, et al. Synthesis and antiproliferative assay of norcantharidin derivatives in cancer cells[J]. Med Chem, 2014,10(4):376-381.
2018, Vol. 29 
